Shenzhen Neptunus Interlong Bio-technique Company Limited

SEHK:8329 Stok Raporu

Piyasa değeri: HK$216.5m

Shenzhen Neptunus Interlong Bio-technique Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shenzhen Neptunus Interlong Bio-technique.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi11.1%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

None

Son güncellemen/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings

Sep 05
Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Apr 19
We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Oct 03
These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

Mar 29
Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

Sep 28
We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Aug 18
A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Jun 06
Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Dec 15
Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

Dec 29
Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Nov 24
Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Shenzhen Neptunus Interlong Bio-technique yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

SEHK:8329 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
6/30/20241,05432108127N/A
3/31/20241,04527N/AN/AN/A
12/31/20231,065243854N/A
9/30/20231,12064N/AN/AN/A
6/30/20231,10364-77-56N/A
3/31/20231,07160N/AN/AN/A
12/31/2022987544261N/A
9/30/202293147N/AN/AN/A
6/30/2022886374660N/A
3/31/202283531N/AN/AN/A
12/31/202183936-85-70N/A
9/30/202186833N/AN/AN/A
6/30/202196338-72-42N/A
3/31/20211,05643N/AN/AN/A
12/31/20201,031375694N/A
9/30/20201,07752N/AN/AN/A
6/30/20201,06559118156N/A
3/31/20201,05957N/AN/AN/A
12/31/20191,081602760N/A
9/30/20191,00656N/AN/AN/A
6/30/201993752-524N/A
3/31/201987947N/AN/AN/A
12/31/201886748-325N/A
9/30/201886243N/AN/AN/A
6/30/201884843-626N/A
3/31/201883551N/AN/AN/A
12/31/201779050N/A56N/A
9/30/201780364N/AN/AN/A
6/30/201777264N/A77N/A
3/31/201777765N/AN/AN/A
12/31/201675963N/A83N/A
9/30/201673837N/AN/AN/A
6/30/201672629N/A43N/A
3/31/201671320N/AN/AN/A
12/31/201572121N/A62N/A
9/30/201566419N/AN/AN/A
6/30/201566223N/A60N/A
3/31/201565031N/AN/AN/A
12/31/201464833N/A39N/A
9/30/201463330N/AN/AN/A
6/30/201463027N/A60N/A
3/31/201460337N/AN/AN/A
12/31/201361236N/A29N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if 8329's forecast earnings growth is above the savings rate (2.3%).

Kazançlar ve Piyasa: Insufficient data to determine if 8329's earnings are forecast to grow faster than the Hong Kong market

Yüksek Büyüme Kazançları: Insufficient data to determine if 8329's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if 8329's revenue is forecast to grow faster than the Hong Kong market.

Yüksek Büyüme Geliri: Insufficient data to determine if 8329's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if 8329's Return on Equity is forecast to be high in 3 years time

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y